Results 71 to 80 of about 4,340 (195)

The Histone‐Lysine N‐Methyltransferase (KMT2) Family in Health and Disease

MedComm, Volume 7, Issue 4, April 2026.
This graphical abstract clarifies KMT2 family dysregulation and disease associations: its member mutations cause epigenetic imbalance and abnormal cell development; Menin/WDR5 inhibitors and other targeted therapies block aberrant epigenetic transcriptional programs, and combined synergistic therapies boost therapeutic efficacy.
Qiu Wang, Zunjie Bo, Ya Zhang, Yun Chen, Zhiyu Wang, Shuangmei Tong, Ajing Xu, Jian Zhang, Yan Liu   +8 more
wiley   +1 more source

Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T‐cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report

Clinical Case Reports
Key Clinical Message Belinostat therapy followed by hematopoietic stem cell transplantation is a promising salvage strategy for heavily pretreated patients with peripheral T‐cell lymphoma.
Sigrid De Wilde, Carlos Graux
doaj   +1 more source

Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang, Jingmin Li, Meihuan Chen, Hailong Huang   +3 more
wiley   +1 more source

Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors [PDF]

ACS Medicinal Chemistry Letters, 2018
Despite promising therapeutic utilities for treatment of hematological malignancies, histone deacetylase inhibitor (HDACi) drugs have not proven as effective in the treatment of solid tumors. To expand the clinical indications of HDACi drugs, we developed novel boron-containing prodrugs of belinostat (2), one of which efficiently releases active 2 ...
Shilong Zheng, Shanchun Guo, Qiu Zhong, Changde Zhang, Jiawang Liu, Lin Yang, Qiang Zhang, Guangdi Wang   +7 more
openaire   +2 more sources

Identification of belinostat metabolites in human plasma using HPLC-DAD & LC-MS/MS analyses.

, 2013
Identification of belinostat metabolites in human plasma using HPLC-DAD & LC-MS/MS analyses.
Win-Lwin Thuya (277890), Mark J. Ratain (25629), Boon-Cher Goh (142783), Sherry Ansher (277899), Winnie Yeo (197426), Ling-Zhi Wang (277888), Jie-Ying Amelia Lau (277891), Soo-Chin Lee (132913), Robert Lim (277895), Seow-Ching Wan (277892), How-Sung Lee (277897), Jacqueline Ramírez (5651281), Ying-Kiat Zee (277894), Anthony Chan (277898), Mei-Yi Michelle Chan (277889), Andrea Li-Ann Wong (277893), Paul C. Ho (277896)   +16 more
core   +1 more source

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice [PDF]

, 2013
Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3'-deoxy-3'-[(18)F ...
Erichsen, Kamille Dumong, Højgaard, Liselotte, Madsen, Jacob, Sehested, Maxwell, Björkling, Fredrik, Maxwell Sehested, Andreas Kjær, Camilla Bardram Johnbeck, Fredrik Björkling, Mette Munk Jensen, Jacob Madsen, Jensen, Mette Munk, Kjær, Andreas, Johnbeck, Camilla Bardram, Kamille Dumong Erichsen, Peter Buhl Jensen, Jensen, Peter Buhl, Liselotte Højgaard   +17 more
core   +1 more source

Tratamiento del cáncer basado en la epigenética

Correo Científico Médico, 2021
El cáncer es una enfermedad multifactorial que involucra a factores genéticos,  epigenéticos y ambientales en una compleja y no bien comprendida interrelación.
Yarimi Rodríguez Moldón, Alexander Expósito Lara, José Antonio Hernández Cárdenas, Regla Cristina Valdés Cabodevilla   +3 more
doaj   +2 more sources

Supplementary Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma

, 2010
Supplementary Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell ...
Enrica Marchi (14976762), Luca Paoluzzi (270905), Owen A. O'Connor (14890776), Luigi Scotto (11213560), Jasmine Zain (14976765), Venkatraman E. Seshan (8031149)   +5 more
core   +1 more source

Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers

Clinical Pharmacology in Drug Development, Volume 15, Issue 3, March 2026.
Abstract Givinostat is a class I/II histone deacetylase inhibitor indicated for Duchenne muscular dystrophy (DMD). The study evaluated the effect of therapeutic and supratherapeutic givinostat doses on the QT/QTc interval. Healthy volunteers received each treatment—givinostat hydrochloride monohydrate oral suspension as a therapeutic (100 mg) or ...
Eugenio Mercuri, Barry Byrne, Tracey Willis, John Bourke, Paolo Bettica, Sara Cazzaniga, Hongqi Xue, Borje Darpo   +7 more
wiley   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source